Ilse Van Hove - Concepedia

Concepedia

Author

Ilse Van Hove

Janssen (Belgium)

Also Known As

I Van Hove, I. Van Hove, Ilse Van Hove, Ilse van Hove, van Hove, Ilse

33

Publications

1.9K

Citations

13

H-Index

30

Concepts

All Affiliations

Janssen (Belgium)Johnson & Johnson (United States)Grünenthal Group (Germany)Janssen (United States)Center for Clinical Research (United States)

IV

About

Ilse Van Hove is an author at Janssen (Belgium) specializing in medicine, psychopharmacology, and psychiatry.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	782
2	Social Sciences	3	3	205
3	Health Sciences	2	2	237
4	Behavioral Sciences	1	1	69
5	Neurology	1	1	93

Ilse Van Hove

×

14

Publications

1.9K

Citations

13

H-Index

	Year	Citations
Risperidone and Haloperidol in First-Episode Psychosis: A Long-Term Randomized Trial Nina R. Schooler, Jonathan Rabinowitz, Michael Davidson, American Journal of Psychiatry	2005	345
Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study Robert Buynak, Douglas Y. Shapiro, Akiko Okamoto, Expert Opinion on Pharmacotherapy	2010	250
Efficacy and Safety of Tapentadol Extended Release Compared with Oxycodone Controlled Release for the Management of Moderate to Severe Chronic Pain Related to Osteoarthritis of the Knee Marc Afilalo, Mila Etropolski, Brigitte Kuperwasser, Clinical Drug Investigation Pain TherapyHealth SciencesPain MedicinePostoperative Pain ManagementChronic Musculoskeletal Condition	2010	226
Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double‐blind, placebo‐controlled study Magali Haas, Melissa P. DelBello, Gahan Pandina, Bipolar Disorders	2009	209
Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: A 10-day, phase III, randomized, double-blind, active- and placebo-controlled study Craig T. Hartrick, Ilse Van Hove, Jens‐Ulrich Stegmann, Clinical Therapeutics Phase IiiOsteoarthritisOrthopaedicsPlacebo-controlled StudyTapentadol Immediate Release	2009	179
Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia Mariëlle Eerdekens, Ilse Van Hove, Bart Remmerie, Schizophrenia Research PsychiatryMedicinePsychotropic MedicationPsychopharmacologySchizophrenia	2004	161
The effects of inhibition of fatty acid amide hydrolase (FAAH) by JNJ-42165279 in social anxiety disorder: a double-blind, randomized, placebo-controlled proof-of-concept study Mark E. Schmidt, Michael R. Liebowitz, Murray B. Stein, Neuropsychopharmacology	2020	95
Risperidone in the Treatment of Psychosis of Alzheimer Disease: Results From a Prospective Clinical Trial Jacobo Mintzer, Andrew Greenspan, Ivo Caers, American Journal of Geriatric Psychiatry Alzheimer's DiseasePsychiatryPsychotic DisorderPsychotropic MedicationDementia	2006	93
The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder Kasper Recourt, Peter de Boer, Rob Zuiker, Translational Psychiatry	2019	74
Efficacy and safety of oral tapentadol extended release in Japanese and Korean patients with moderate to severe, chronic malignant tumor-related pain Keiichiro Imanaka, Yushin Tominaga, Mila Etropolski, Current Medical Research and Opinion	2013	70

Page 1